JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.